Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0309)
Name
Necrostatin-1
Synonyms
Necrostatin-1; 4311-88-0; MTH-DL-Tryptophan; Necrostatin 1; Nec-1; 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone; 5-((1H-indol-3-yl)methyl)-3-methyl-2-thioxoimidazolidin-4-one; MTH-trp; methyl-thiohydantoin-tryptophan; 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one; Necrostatin-1 inactive control; 4-imidazolidinone, 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-; Methylthiohydantoin-DL-tryptophan;MTH-DL-tryptophan; 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxoimidazolidin-4-one; MFCD00056916; NECROSTATIN; CID2828334; Oprea1_645908; CBDivE_006695; MLS006011643; SCHEMBL856922; CHEMBL195008; GTPL9750; methylthiohydantoin-DL-tryptophan; BDBM36371; CHEBI:91658; DTXSID40385186; HMS3229H21; HMS3268N04; HMS3413G04; HMS3653J04; HMS3673K15; HMS3677G04; BCP06760; EX-A2108; Necrostatin-1, >=98% (HPLC); s8037; STL452869; STL511330; AKOS001662677; AKOS016050497; AKOS023092523; CCG-265032; CS-1666; NCGC00092372-01; NCGC00092372-02; NCGC00092372-03; NCGC00092372-15; AC-32084; AS-10165; HY-15760; SMR001375661; FT-0635218; N1174; SW219795-1; EC-000.2418; AB00073999-01; A826160; BRD-A36318220-001-01-3; Q27163481; Hydantoin, 5-(indol-3-ylmethyl)-3-methyl-2-thio- (7CI,8CI); 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone; 4-Imidazolidinone, 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo- (9CI); 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone, Nec-1; 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanyl-3,5-dihydro-4H-imidazol-4-one; 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-imidazolidin-4-one;Necrostatin 1

    Click to Show/Hide
Structure
Formula
C13H13N3OS
IUPAC Name
5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one
Canonical SMILES
CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32
InChI
InChI=1S/C13H13N3OS/c1-16-12(17)11(15-13(16)18)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,11,14H,6H2,1H3,(H,15,18)
InChIKey
TXUWMXQFNYDOEZ-UHFFFAOYSA-N
PubChem CID
2828334
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model Huh-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0336
SK-HEP-1 cells Liver and intrahepatic bile duct epithelial neoplasm Homo sapiens CVCL_0525
Response regulation Necrostatin-1 potentiated sulfasalazine-induced expression of SLC7A11, a catalytic subunit of system xc- in these cells. And necrostatin-1 Prevents Ferroptosis in a RIPK1- and IDO-Independent Manner in Hepatocellular Carcinoma.
References
Ref 1 Necrostatin-1 Prevents Ferroptosis in a RIPK1- and IDO-Independent Manner in Hepatocellular Carcinoma. Antioxidants (Basel). 2021 Aug 25;10(9):1347. doi: 10.3390/antiox10091347.